Mycro-3-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEMycro3Cat.No.:HY-100669CASNo.:944547-46-0分?式:C??H??ClF?N?O?分?量:526.88作?靶點(diǎn):c-Myc;Autophagy作?通路:Apoptosis;Autophagy儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:≥100mg/mL(189.80mM)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.8980mL9.4898mL18.9797mL5mM0.3796mL1.8980mL3.7959mL10mM0.1898mL0.9490mL1.8980mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>90%cornoil1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:2.5mg/mL(4.74mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性Mycro3?種具有?服活性的、有效的選擇性Myc-Max?聚化抑制劑[1]。Mycro3可?于胰腺癌的研究。IC50&TargetMyc-MAXdimerization[1]體外研究Mycro3isapotentandselectivec-Mycinhibitorinwholecellassays,withweakinhibitoryactivityagainstActivatorprotein1(AP-1).Mycro3hasasuperiorspecificityprofiletoitspredecessors.Mycro3inhibitstheinteractionbetweenc-MycandMax.Mycro3hashighselectivityandinhibitsc-Myc/MaxdimerizationandconjugationwithDNA[1].Mycro3exhibitsanexcellentspecificitywithIC50sof0.25and9.0μMforcellswithintactMycallelesandMyc-nullcells,respectively[2].體內(nèi)研究Mycro3(100mg/kg;oraladministration;dailyfortwomonths)inducesmarkedshrinkageofpancreaticductaladenocarcinoma(PDA),increasescancercellapoptosis,andreducescellproliferation.TumorgrowthisalsodrasticallyattenuatedinMycro3-treatedNOD/SCIDmicecarryingorthotopicorheterotopicxenograftsofhumanpancreaticcancercells[2].AnimalModel:MoribundPdx1-cre/KRAS*micebearingpancreaticductaladenocarcinoma(PDA)[2]Dosage:100mg/kgAdministration:Oraladministration;dailyfortwomonthsResult:Increasedsurvivaltime.Mycro3administrationwasdiscontinuedaftertwomonths,themousesurvivedforanadditionalmonth.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?CellMolImmunol.2022Sep;19(9):1030-1041.?CellDeathDis.2020Sep15;11(9):760.?CancerCellInt.2021Dec14;21(1):670.?ResearchSquarePreprint.2021Sep.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].ChenBJ,etal.Smallmoleculestargetingc-Myconcogene:promisinganti-cancertherapeutics.IntJBiolSci.2014Sep13;10(10):1084-96.[2].DimitrisStellas,etal.Therapeuticeffectsofananti-Mycdrugonmousepancreaticcancer.JNatlCancerInst.2014Oct2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE11;106(12):dju320.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedic